All In Biotech

Drug Trial Radar · NCT06741397

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

A Phase 2b Single Arm, Repeat Dose Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of A New Formulation of Cabotegravir LA Injected Intramuscularly Q4M in Adolescent and Adult Participants at Risk of HIV Acquisition

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 229 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

229

Actual

Start

Dec 20, 2024

Primary completion

Sep 9, 2026

Study completion Aug 30, 2029

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.

Conditions

  • HIV Infections

Interventions

  • CAB LADrug

    Injections administered IM gluteal.

  • New formulation of CAB LADrug

    Injections administered IM gluteal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CAB trough concentrations for target of 1.05 microgram per milliliter (μg/mL) for men and 1.39 μg/mL for womenTime frame: From Month 13 to Month 25

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    Doral, Florida

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Springfield, Massachusetts

  • GSK Investigational Site

    Berkley, Michigan

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Hawthorne, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    San Juan, Puerto Rico

  • GSK Investigational Site

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.